Amphastar Pharmaceuticals (NASDAQ:AMPH) will announce its earnings results after the market closes on Thursday, November 8th. Analysts expect the company to announce earnings of $0.12 per share for the quarter.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.05). Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. The business had revenue of $71.00 million during the quarter, compared to analyst estimates of $64.22 million. During the same period in the previous year, the firm posted $0.11 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, analysts expect Amphastar Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of AMPH stock traded down $0.12 on Tuesday, hitting $18.83. The company’s stock had a trading volume of 216 shares, compared to its average volume of 113,675. The company has a current ratio of 1.94, a quick ratio of 1.24 and a debt-to-equity ratio of 0.11. Amphastar Pharmaceuticals has a fifty-two week low of $14.40 and a fifty-two week high of $20.45. The firm has a market cap of $868.23 million, a PE ratio of 49.51, a PEG ratio of 8.56 and a beta of 1.38.
In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $17.82, for a total value of $178,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William J. Peters sold 2,407 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $17.59, for a total transaction of $42,339.13. Following the completion of the sale, the chief financial officer now owns 86,836 shares of the company’s stock, valued at approximately $1,527,445.24. The disclosure for this sale can be found here. Company insiders own 31.50% of the company’s stock.
A number of research analysts have weighed in on the stock. BidaskClub lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 13th. Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Needham & Company LLC cut their target price on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 10th. Finally, ValuEngine raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Three research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $21.40.
TRADEMARK VIOLATION WARNING: “Amphastar Pharmaceuticals (AMPH) to Release Quarterly Earnings on Thursday” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/11/06/amphastar-pharmaceuticals-amph-to-release-quarterly-earnings-on-thursday.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.